The Upsher-Smith Promise of Support® Program Our company-backed program helps streamline access to KYMBEE™ (deflazacort) by reducing administrative demands on your practice and coordinating support for caregivers. Access and coverage coordination We help navigate coverage requirements and reduce administrative burden so your team can stay focused on patient care—not paperwork. Benefits investigation and coverage clarification Coverage navigation, including prior authorization and appeal assistance $0 copay* for eligible commercially insured patients Pathways to access therapy, even when insurance challenges arise *Limitations apply. Therapy initiation and continuity We offer resources designed to help patients start and stay on KYMBEE therapy. Quick Start during the insurance approval process Bridge Supply for coverage gaps or refill delays Free home delivery with weather monitoring to prevent delays Reliable and consistent medication support and supply 24/7 pharmacist access and medication refill reminders Language translation services to support caregivers and families Learn more about prescribing KYMBEE Why consider switching your patients now? There are several factors to consider in Duchenne muscular dystrophy (DMD) treatment. Help parents better understand their child’s situation and what switching may offer. Deflazacort clinical confidenceFounded in research and real-world experience KYMBEE (deflazacort) tablets were first approved by the U.S. Food and Drug Administration (FDA) in 2024, but researchers began studying the deflazacort molecule many years earlier. In fact, international research on deflazacort for DMD began as early as the 1980s. In 2017, deflazacort became the first corticosteroid approved by the FDA for DMD.* Now backed by more than 30 years of clinical experience, including both short- and long-term clinical studies, deflazacort offers clinicians a treatment option with a demonstrated safety and efficacy profile, and substantial real-world experience to help guide their patients through the treatment journey.1,2 Support to help patients transition: For patients facing prior coverage barriers, the program streamlines prior authorization and appeal processes. For patients who are changing from a different steroid (e.g., prednisone or prednisolone), the program can enable a smooth transition to deflazacort. For patients new to therapy, the program offers proactive benefits investigation to help ensure therapy begins without delay. Acute adrenal insufficiency can occur if corticosteroids are withdrawn abruptly and can be fatal. The degree and duration of adrenocortical insufficiency produced is variable among patients and depends on the dose, frequency, and duration of corticosteroid therapy. The risk is reduced by gradually tapering the corticosteroid dose when withdrawing treatment. If you are caring for a patient aged 5 years or older with DMD who is a candidate for deflazacort therapy, now is an ideal time to consider KYMBEE. Switching your patients to KYMBEE * The innovator deflazacort approved by the FDA in 2017 was EMFLAZA®. KYMBEE (deflazacort) tablets are a generic AB-rated, therapeutically equivalent version of EMFLAZA (deflazacort) tablets for the treatment of DMD in patients 5 years of age or older. FDA-approved generic medicines work in the same way and are expected to have the same clinical benefit and risks as their brand-name counterparts. A generic medicine is required to be the same as a brand-name medicine in dosage, safety, effectiveness, strength, stability, and quality, as well as in the way it is taken. Access tools and information to help you prescribe KYMBEE with confidence. KYMBEE Prescription Form Resources Explore FAQs References: 1. Deflazacort, eteplirsen, and golodirsen for Duchenne muscular dystrophy: effectiveness and value. Institute for Clinical and Economic Review (ICER). August 15, 2019. Accessed February 4, 2026. https://icer.org/wp-content/uploads/2020/10/ICER_DMD-Final-Report_081519-2-1.pdf 2. Orange book: approved drug products with therapeutic equivalence evaluations. US Food and Drug Administration. Updated October 2025. Accessed February 4, 2026. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm IMPORTANT SAFETY INFORMATION & INDICATION FOR KYMBEE™ (deflazacort) Tablets IMPORTANT SAFETY INFORMATION Contraindications: KYMBEE is contraindicated in patients with a hypersensitivity to deflazacort or any of the inactive ingredients. Warnings & Precautions Alterations in Endocrine Function: Corticosteroids, such as KYMBEE, can cause serious and life-threatening alterations in endocrine function, especially with chronic use. Monitor patients receiving KYMBEE for Cushing’s syndrome, hyperglycemia, and adrenal insufficiency after KYMBEE withdrawal. In addition, patients with hypopituitarism, primary adrenal insufficiency or congenital adrenal hyperplasia, altered thyroid function, or pheochromocytoma may be at increased risk for adverse endocrine events. Acute adrenal insufficiency or “withdrawal syndrome” can occur if corticosteroids are withdrawn abruptly and can be fatal. The risk is reduced by gradually tapering the corticosteroid dose when withdrawing treatment. During times of stress, corticosteroid dosage may need to be increased. Immunosuppression and Increased Risk of Infection: Increased risk of new, exacerbation, dissemination, or reactivation of latent infections, which can be severe and at times fatal; signs and symptoms of infection may be masked. Monitor for the development of infection and consider KYMBEE withdrawal or dosage reduction as needed. Tell patients and/or caregivers to inform their healthcare provider if the patient has had recent or ongoing infections or if they have recently received a vaccine. Warn patients who are on corticosteroids who have not had chickenpox or measles to avoid exposure to chickenpox or measles and to alert their healthcare provider immediately if they are exposed. Alterations in Cardiovascular/Renal Function: Monitor for elevated blood pressure. Dietary salt restriction and potassium supplementation may be necessary. KYMBEE should be used with caution in patients with congestive heart failure, hypertension, or renal insufficiency. Gastrointestinal Perforation: Increased risk of gastrointestinal perforation during corticosteroid use in patients with certain gastrointestinal disorders such as active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and non-specific ulcerative colitis. Signs and symptoms may be masked. Behavioral and Mood Disturbances: May include euphoria, insomnia, mood swings, personality changes, severe depression, and psychosis. Symptoms typically emerge within a few days or weeks of starting treatment and may be dose-related. Inform patients or caregivers of the potential for behavioral and mood changes and encourage them to seek medical attention if psychiatric symptoms develop, especially if depressed mood or suicidal ideation is suspected. Effects on Bones: The risk of osteoporosis increases with prolonged use of KYMBEE, which can predispose patients to vertebral and long bone fractures. Monitor for decreases in bone density with chronic use of KYMBEE. Ophthalmic Effects: May include cataract formation, ocular infections, and glaucoma. If treatment with corticosteroids, including KYMBEE, are continued for more than 6 weeks, monitor intraocular pressure. Vaccination: Do not administer live or live attenuated vaccines to patients receiving immunosuppressive doses of corticosteroids. Administer live-attenuated or live vaccines at least 4 to 6 weeks prior to starting KYMBEE. Serious Skin Rashes: Toxic epidermal necrolysis has been reported with the use of deflazacort. Discontinue at the first sign of rash, unless the rash is clearly not drug related. Effects on Growth and Development: Long-term use of corticosteroids, including KYMBEE, can have negative effects on growth and development in children. Thromboembolic Events: Observational studies have shown an increased risk of thromboembolism. Use KYMBEE with caution in patients who have or may be predisposed to thromboembolic disorders. Adverse Reactions: The most common adverse reactions (incidence 10% and greater than placebo) are Cushingoid appearance, weight increased, increased appetite, upper respiratory tract infection, cough, pollakiuria, hirsutism, central obesity, and nasopharyngitis. Drug Interactions: Give one third of the recommended dose of KYMBEE when KYMBEE is administered with strong or moderate CYP3A4 inhibitors. Avoid use of strong or moderate CYP3A4 inducers with KYMBEE, as they may reduce efficacy. This safety information is not comprehensive. Please see the full Prescribing Information for KYMBEE. You can also visit www.upshersmith.com or call 1-888-650-3789. You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-888-650-9180 or to the FDA by visiting www.fda.gov/medwatch. INDICATION KYMBEE (deflazacort) Tablets are indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older.